Michel Janicot, PhD
acting Chief Development Officer
Michel holds a Ph.D. degree in Biochemistry (Molecular and Cellular Biology) from University Paris VII (France) and was Postdoctoral Fellow at The Johns Hopkins University (Baltimore, MD. USA). He has over 35 years of professional experience in Oncology preclinical and early clinical pharmaceutical drug development in increasing leadership roles at Rhone-Poulenc Rorer (Sanofi) and Janssen (Johnson & Johnson).
Since 2012, Michel is the Founder and Managing Director of JMi ONConsulting, a consulting firm specialized in providing services and guidances for pharmaceutical R&D programs in the field of Oncology, Inflammation, Immunology, Fibrosis and Ophthalmology. He is also co-founder and Board member of aPODD, a non-profit foundation focusing on Pediatric Oncology Drug Development.
Michel has a long-lasting hands-on experience and strategic expertise and multidisciplinary network in the discovery and development of RNA-based therapeutics (mRNAs, miRNA/siRNAs, and ASOs) with strategic focus in oncology therapeutic intervention. Michel joined InteRNA in 2016.